116632-62-3Relevant articles and documents
Synthesis of aza mono, bi and tricyclic compounds. Evaluation of their anti MDR activity
Gallo, Sandrine,Atifi, Siham,Mahamoud, Abdallah,Santelli-Rouvier, Christiane,Wolfart, Krisztina,Molnar, Jozsef,Barbe, Jacques
, p. 19 - 26 (2003)
Anti MDR activity of a series of acridine, pyridoquinoline, quinoline and pyridine analogous amines was evaluated. Interesting activity is displayed by tricyclic compounds. Besides ring size, influence of the side chain was studied.
The interaction between resistance modifiers such as pyrido[3,2-g] quinoline, aza-oxafluorene and pregnane derivatives with DNA, plasmid DNA and tRNA
Sharples, Derek,Spengler, Gabriella,Molnár, Joseph,Antal, Zsuzsanna,Molnár, Annamária,Kiss, János T.,Szabó, József A.,Hilgeroth, Andreas,Gallo, Sandrine,Mahamoud, Abdallah,Barbe, Jacques
, p. 195 - 202 (2007/10/03)
Various resistance mechanisms such as complex formation with DNA, tRNA and MDR1 p-glycoprotein were modified in bacteria and cancer cells in presence of pregnane, pyridoquinoline, and aza-oxafluorene derivatives. Interaction between the compounds, plasmid
Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
-
, (2008/06/13)
This invention involves compounds having the following structure: as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.
